Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Full year ended December 31, 2024
Filing Date: February 5, 2025
Novo Nordisk reported record financial performance for 2024, driven primarily by double-digit growth in its Diabetes and Obesity care segments. The company completed the acquisition of three manufacturing sites from Novo Holdings in connection with the broader Catalent transaction in December 2024. The company treats approximately 45.2 million patients globally.
Key Financial Metrics
| Metric (DKK Million) | 2024 | 2023 | Growth (Reported) | Growth (CER*) |
|---|---|---|---|---|
| Net Sales | 290,403 | 232,261 | 25% | 26% |
| Operating Profit | 128,339 | 102,574 | 25% | 26% |
| Net Profit | 100,988 | 83,683 | 21% | N/A |
| Diluted EPS (DKK) | 22.63 | 18.62 | 22% | N/A |
| EBITDA | 147,446 | 111,987 | 32% | 33% |
| Free Cash Flow | (14,707) | 68,326 | (122%) | N/A |
| Capital Expenditure (PP&E) | 47,164 | 25,806 | 83% | N/A |
| Total Assets | 465,795 | 314,486 | 48% | N/A |
| Equity | 143,486 | 106,561 | 35% | N/A |
*CER: Constant Exchange Rates (average 2023 rates).
Material Changes vs. Prior Period
- Sales Growth: Total sales increased 25% (26% at CER). North America Operations grew 30%, while International Operations grew 17% (19% at CER).
- Therapeutic Drivers:
- Obesity Care: Sales surged 56% (57% at CER) to DKK 65.1 billion, driven by Wegovy (up 86%).
- Diabetes Care: Sales grew 19% (20% at CER) to DKK 206.6 billion. GLP-1 diabetes sales increased 21% (22% at CER), led by Ozempic (up 26%).
- Rare Disease: Sales increased 9% to DKK 18.6 billion.
- Profitability: Operating margin remained stable at 44.2%. Gross margin improved slightly to 84.7% due to product mix and US gross-to-net adjustments, partially offset by capacity expansion costs.
- Costs: R&D costs rose 48% to DKK 48.1 billion due to late-stage trials and impairment losses. Sales and distribution costs increased 9% to DKK 62.1 billion.
- Cash Flow: Free cash flow turned negative (DKK -14.7 billion) primarily due to the DKK 82.2 billion cash outflow for the acquisition of three Catalent manufacturing sites and increased capital expenditure.
- Impairments: Operating profit was negatively impacted by impairment losses related to intangible assets, including a DKK 5.7 billion loss in Q2 related to ocedurenone.
Guidance, Outlook, and Risks
2025 Outlook
- Sales Growth: Expected 16-24% at CER (approx. 3 percentage points higher in DKK).
- Operating Profit Growth: Expected 19-27% at CER (approx. 5 percentage points higher in DKK).
- Free Cash Flow: Expected DKK 75-85 billion (excluding business development impact).
- Capital Expenditure: Expected around DKK 65 billion to expand global supply chain capacity.
- Financial Items: Expected net loss of around DKK 9 billion due to FX hedging losses and interest expenses from debt-financed acquisitions.
- Tax Rate: Expected effective tax rate of 21-23%.
Management Commentary
CEO Lars Fruergaard Jørgensen highlighted that 26% sales growth reflects over 45 million people benefiting from treatments. The company is focusing on commercial execution, R&D pipeline progression (including CagriSema and amycretin), and expanding production capacity to address periodic supply constraints and drug shortages.
Risks and Contingencies
- Supply Constraints: Continued periodic supply constraints and drug shortage notifications across products and geographies due to high demand.
- Legal:
- Settlements reached with generic manufacturers regarding ANDAs for Ozempic, Wegovy, and Rybelsus.
- Securities class-action lawsuit filed in January 2025 regarding REDEFINE 1 trial disclosures; management does not expect a material financial impact.
- Regulatory: Risks related to healthcare reforms, legislative changes, and the 340B Drug Pricing Program in the US.
- FX Risk: Significant exposure to USD/DKK exchange rates; hedging strategies are in place but result in net losses in 2024 and expected in 2025.
Dividends
The Board proposes a final dividend of DKK 7.90 per share, bringing the total 2024 dividend to DKK 11.40 per share (a 21% increase). The payout ratio is approximately 50.2%.
Investor Verification Checklist
- Supply Chain Capacity: Verify the timeline and sufficiency of new manufacturing capacity (including the acquired Catalent sites) to meet demand for GLP-1 products and alleviate shortages.
- Free Cash Flow Recovery: Monitor the trajectory of free cash flow in 2025 to ensure it meets the DKK 75-85 billion guidance despite high CAPEX and debt servicing costs.
- R&D Pipeline Milestones: Track regulatory approval timelines for CagriSema (expected filing Q1 2026) and oral semaglutide 25 mg for obesity.
- US Gross-to-Net Adjustments: Assess the sustainability of the positive impact from US gross-to-net sales adjustments on operating profit.
- Legal Proceedings: Monitor the status of the securities class-action lawsuit and any potential outcomes of the 340B program litigation.
- Competition: Evaluate the impact of intensifying competition in the obesity and diabetes markets on pricing and market share.